undamentalytics Newsletter
Sign in

Inmune Bio, Inc. balance sheet

At the end of fiscal 2025, Inmune Bio, Inc. had total assets of $32.4m, total liabilities of $8.8m and shareholders' equity of $23.5m. It held $24.8m in cash against $0 of debt: net cash of $24.8m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents10227552362125
Receivables—————214
Total current assets21248365402330
Total assets18174110082574032
Total current liabilities—124111878
Short-term debt————510——
Long-term debt———1510—15—
Total debt000151510150
Total liabilities01220221979
Shareholders' equity1817398060373224
Net debt (negative = net cash)−1−0−22−60−37−26−6−25
Shares outstanding—9m13m18m18m18m22m27m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: INMB vs LYELAIM vs INMBIBIO vs INMB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inmune Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inmune Bio, Inc.